FOLLI, FRANCO
FOLLI, FRANCO
Dipartimento di Scienze della Salute
Low, non-psychedelic doses of psilocybin as a novel treatment for MASLD, obesity and type 2 diabetes via 5-HT2B receptor-dependent mechanisms
2026 M. Colognesi, D. Gabbia, A. Signor, M. Sarill, L. Centofanti, A. Rinaldi, L. Cascione, S. Nunziata, M. Banzato, A. Mattarei, G. Finzi, S. Sonda, D. Pendin, I. Zanotto, S. Comai, G. Pasut, A. Alajati, M. Saponaro, L. Bucciarelli, M.E. Lunati, G. Guarato, I. Goggi, S. La Rosa, C. Morano, R.C. Paroni, M.V. Dei Cas, G. Daniele, M. Gentilucci, M. Pappagallo, A. Alimonti, P.L. Manfredi, F. Folli, S. De Martin
Differential Regulation of Noncanonical (Deoxy- and Deoxymethyl-) Sphingolipids Biosynthesis in Type 1 and Type 2 Diabetes Mellitus
2026 L. Centofanti, C. Morano, M.V. Dei Cas, P. Zermiani, U. Mortola, M. Bignotto, G. Serrao, P.M. Battezzati, R. Paroni, F. Folli
The interaction between glucose levels and body mass index on the regulation of the circulating sphingolipidome in humans
2026 C. Morano, L. Centofanti, M. Dei Cas, R. Zanzi, G. De Pinto, M. Bignotto, P. Zermiani, E. Bianco, F. Samartin, S. Penati, I. Pes, I. Goggi, P. Senesi, G. Serrao, L. Bucciarelli, F. Bravi, A. Russo, M. Trinchera, P. Battezzati, M. Ferraroni, F. Folli, R. Paroni
Synergic effect of diet and polysaccharide-based complex administration in the treatment of children and adolescents with metabolically unhealthy obesity: the Polymets Study
2026 G. Fiore, A. Altayeva, S. Panelli, D. De Zan, L. Sterzi, V. Calcaterra, M. Tosi, F. Folli, G. Zuccotti, F. Comandatore, E. Verduci
Long-Term Safety and Efficacy of Esmethadone in Patients With Major Depressive Disorder
2025 M. Fava, L. Pani, S.D. Martin, A.J. Cutler, C.W. Gorodetzky, F.J. Vocci, F.L. Sapienza, T.R. Kosten, C. Kröger, P. Champasa, C. Guidetti, S. Comai, A. Mattarei, F. Folli, D. Bushnell, S. Traversa, C.E. Inturrisi, P.L. Manfredi, M. Pappagallo
Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Antidepressant Tachyphylaxis
2025 C. Guidetti, G.I. Papakostas, L. Pani, S.D. Martin, G. Serra, M. Apicella, C. Kröger, P. Champasa, S. Comai, A. Mattarei, F. Folli, M. Pappagallo, P.L. Manfredi, M. Fava
Reply to the letter comment of Su Boon Yong MD, PhD and colleagues to: Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE− 2 study
2025 C. Berra, R. Manfrini, F. Bifari, E. Cipponeri, R. Ghelardi, L. Centofanti, U. Mortola, E. Lunati, L. Bucciarelli, V. Cimino, F. Folli
Continuous interstitial glucose monitoring in diabetic and non-diabetic critically ill patients is simple and accurate: comparison with venous, arterial and capillary glucose measurements
2025 D. Chiumello, M. Passeri, S. Coppola, E. Chiodaroli, S. Carnier, M. Montante, T. Pozzi, I. Goggi, F. Bifari, U. Mortola, L. Centofanti, F. Folli
Analysis of morbid obese diabetic and non-diabetic patients: clinical and social characteristics, habits and workup to undergo bariatric surgery in Lombardy, Italy
2025 A.E. Pontiroli, S. Guarino, M. Tagliabue, L. La Sala, L. Centofanti, S. Olmi, G. Sarro, A. Giovanelli, C. Asteria, E. Galfrascoli, U. Mortola, L. Bucciarelli, M.A. Zappa, E. Tagliabue, F. Folli
Lipidome profile of Cystic Fibrosis Related Diabetes, Type 1 and Type 2 Diabetes Mellitus: potential links to inflammation and glucose and lipid metabolism
2025 A. Mingione, C. Loretelli, M. Dei Cas, F. Pivari, M. Barcella, I. Merelli, A. Zulueta, R. Paroni, L.C. Morlacchi, V. Vaira, F. Gillani, M. Piccoli, L. Anastasia, E. Albi, I. Righi, M. Nosotti, P. Fiorina, A. Caretti, L. Rosso, F. Folli, P. Signorelli
TMEM219 signaling promotes intestinal stem cell death and exacerbates colitis
2025 F. D'Addio, G. Amabile, E. Assi, A. Maestroni, A. Petrazzuolo, C. Loretelli, A. Abdelasalam, M. Ben Nasr, I. Pastore, M.E. Lunati, V. Usuelli, M. Zocchi, A.J. Seelam, D. Corradi, S. La Rosa, V. Marin, M. Zangarini, M. Nardini, S. Porzio, F. Canducci, C. Nardini, B. El Essawy, M. Nebuloni, J. Yang, M. Venturini, G. Maconi, F. Folli, S. Danese, G. Zuccotti, G.M. Sampietro, S. Ardizzone, P. Fiorina
Synergistic effects of glucose tolerance and BMI on cardiovascular events and all-cause mortality in a healthy population. CA.ME.LI.A study 7 year follow-up
2024 M. Bignotto, E. Bianco, L. Centofanti, A. Russo, M. Dei Cas, P. Zermiani, C. Morano, F. Samartin, E. Bertolini, F. Bifari, C. Berra, M. Zuin, R. Paroni, P.M. Battezzati, F. Folli
Effect of Time From Onset of Major Depressive Disorder on the Therapeutic Response to Esmethadone (REL-1017)
2024 C. Guidetti, S.D. Martin, G. Serra, M. Apicella, L. Pani, M. Pappagallo, A. Mattarei, F. Folli, P. Manfredi, M. Fava
The Relationship of Glucose Intolerance/Diabetes and Overweight/Obesity with Sphingolipidoma Alterations
2024 C. Morano, L. Centofanti, M.V. DEI CAS, S. Penati, E. Bianco, M. Bignotto, C. Berra, P. Zermiani, R. Paroni, P.M. Battezzati, F. Folli
Investigating the Impact of Epstein-Barr Virus on Sphingolipid Composition in Extracellular Vesicles of Multiple Sclerosis Patients
2024 L. Centofanti, A. Zollo, M. Dei Cas, V. Citro, D. Giannandrea, E. Soleymaninejadian, A. Mingione, A. Corona, A. Priori, M. Miozzo, F. Folli, R. Paroni, R. Chiaramonte, F. Martinelli Boneschi
Type 2 diabetes mellitus pharmacological remission with dapagliflozin plus oral semaglutide
2024 M.E. Lunati, V. Cimino, D. Bernasconi, A. Gandolfi, P.S. Morpurgo, C. Tinari, E. Lazzaroni, L. Baruffaldi, M. Muratori, L. Montefusco, I. Pastore, A. Rossi, I.G. Franzetti, F. Muratori, R. Manfrini, O.E. Disoteo, R. Terranova, P. Desenzani, A. Girelli, R. Ghelardi, F. D'Addio, M. Ben Nasr, C. Berra, F. Folli, L. Bucciarelli, P. Fiorina
Hyperglycemia impairs EAAT2 glutamate transporter trafficking and glutamate clearance in islets of Langerhans: implications for type 2 diabetes pathogenesis
2024 A. Galli, S. Moretti, N. Dule, E.S. Di Cairano, M. Castagna, P. Marciani, C. Battaglia, F. Bertuzzi, I. Pastore, P. Fiorina, S. La Rosa, A. Davalli, F. Folli, C. Perego
Glucagon-like peptide 1 receptor is a T cell-negative costimulatory molecule
2024 M. Ben Nasr, V. Usuelli, S. Dellepiane, A.J. Seelam, T.V. Fiorentino, F. D'Addio, E. Fiorina, C. Xu, Y. Xie, H.B. Balasubramanian, E. Castillo-Leon, L. Loreggian, A. Maestroni, E. Assi, C. Loretelli, A. Abdelsalam, B. El Essawy, S. Uccella, I. Pastore, M.E. Lunati, G. Sabiu, A. Petrazzuolo, G. Ducci, E. Sacco, L. Centofanti, M. Venturini, S. Mazzucchelli, D. Mattinzoli, M. Ikehata, G. Castellano, G. Visner, L. Kaifeng, K.M. Lee, Z. Wang, D. Corradi, S. La Rosa, S. Danese, J. Yang, J.F. Markmann, G.V. Zuccotti, R. Abdi, F. Folli, P. Fiorina
Efficacy and Safety of Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants: A Phase 3 Randomized Controlled Trial
2024 M. Fava, S.M. Stahl, L. Pani, S.D. Martin, A.J. Cutler, V. Maletic, C.W. Gorodetzky, F.J. Vocci, F.L. Sapienza, T.R. Kosten, C. Kröger, P. Champasa, C. O'Gorman, C. Guidetti, A. Alimonti, S. Comai, A. Mattarei, F. Folli, D. Bushnell, S. Traversa, C.E. Inturrisi, P.L. Manfredi, M. Pappagallo
Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE-2 study
2024 C. Berra, R. Manfrini, F. Bifari, E. Cipponeri, R. Ghelardi, L. Centofanti, U. Mortola, E. Lunati, L. Bucciarelli, V. Cimino, F. Folli